Hints and tips:
Related Special Reports
Related Topics
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Read more on Pfizer here...
...Data on Pfizer’s once-daily oral pill is expected in the first half of 2024. Its shares fell 4.3 per cent lower before the open in New York. Read more on Pfizer here...
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...Pfizer swung to a loss in the third quarter after a $5.6bn inventory write-off related to its Covid-19 antiviral and vaccine....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Pfizer revised its full-year revenue guidance to a range between $58bn and $61bn, down from $67bn-$70bn, “solely due to Covid products”, it said....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Pfizer’s revenue more than halved in the second quarter, after demand for its Covid-19 products fell sharply....
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...Haleon was born as a joint venture between Pfizer and GSK in 2019 that sat within GSK, before it was spun off via a UK listing in 2022, leaving GSK and Pfizer with 13.5 per cent and 32 per cent of the business...
Case studies in best practice among general counsel and company legal teams in North America
...The maker of Panadol painkillers, which was spun off from GSK and Pfizer in 2022, said it expected organic revenue growth of 4-6 per cent in 2024, ahead of analyst estimates of 4.5 per cent....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...“Nobody at Pfizer ever told Mr Dagar, who was on the ‘blinded’ side, the results of the Paxlovid trial,” he added....
...US prosecutors have charged a former Pfizer employee, a Massachusetts police chief, a former pharmaceutical executive and investors into a Donald Trump media venture with insider trading, as part of a wide-ranging...
...Pfizer said it would continue testing an alternative oral obesity drug called danuglipron, which has not raised similar concerns during clinical trials....
...Share moves to note on the New York Stock Exchange include Vertex Pharmaceuticals, Apple and Pfizer: Apple gained 1.7 per cent to a record high close of $197.96 a share....
International Edition